Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewPEAQX tetrasodium salt is a potent NMDA receptor antagonist (IC50 = 8 nM). Exhibits >100-fold selectivity for hGluN2A (formally hNR2A) containing receptors over hGluN2B (hNR2B). Anticonvulsant in vivo.
Please refer to IUPHAR Guide to Pharmacology for the most recent naming conventions.
M. Wt | 542.14 |
Formula | C17H13BrN3Na4O5P |
Storage | Store at -20°C |
Purity | ≥98% (HPLC) |
PubChem ID | 76900415 |
InChI Key | QBVOZIDKUFSQIL-LPOFVUTESA-J |
Smiles | C[C@@H](C3=CC=C(Br)C=C3)NC(P([O-])([O-])=O)C1=C2C(N=C([O-])C([O-])=N2)=CC=C1.[Na+].[Na+].[Na+].[Na+] |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
water | 5.42 | 10 with gentle warming |
The following data is based on the product molecular weight 542.14. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 18.45 mL | 92.23 mL | 184.45 mL |
0.5 mM | 3.69 mL | 18.45 mL | 36.89 mL |
1 mM | 1.84 mL | 9.22 mL | 18.45 mL |
5 mM | 0.37 mL | 1.84 mL | 3.69 mL |
References are publications that support the biological activity of the product.
Auberson et al (2002) 5-Phosphonomethylquinoxalinediones as competitive NMDA receptor antagonists with a preference for the human 1A/2A, rather than 1A/2B receptor composition. Bioorg.Med.Chem.Lett. 12 1099 PMID: 11909726
If you know of a relevant reference for PEAQX tetrasodium salt, please let us know.
Keywords: PEAQX tetrasodium salt, PEAQX tetrasodium salt supplier, NVP-AAM, 077, anticonvulsants, potent, selective, NMDA, subtype, antagonists, antagonism, 459836-30-7, 2102348-87-6, Receptors, 5018, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for PEAQX tetrasodium salt include:
Pavel et al (2021) Anticonvulsant Action of GluN2A-Preferring Antagonist PEAQX in Developing Rats. Pharmaceutics 13 PMID: 33808912
Eckart D et al (2022) Ca2+ signaling in postsynaptic neurons: Neuroplastin-65 regulates the interplay between plasma membrane Ca2+ ATPases and ionotropic glutamate receptors. Cell Calcium 106 102623 PMID: 35853264
Do you know of a great paper that uses PEAQX tetrasodium salt from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review PEAQX tetrasodium salt and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.